



Soliris (eculizumab) and Ultomiris (ravulizumab-cwvz) Medical Drug Criteria Program Summary

POLICY REVIEW CYCLE

Effective Date
11/1/2022

Date of Origin

FDA APPROVED INDICATIONS AND DOSAGE

Agent(s)	FDA Indication(s)	Notes	Ref#
Soliris® (eculizumab) Injection for intravenous use	<ul style="list-style-type: none"> Treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis Treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy <p>Limitation of Use:</p> <p>Soliris is not indicated for the treatment of patients with Shiga toxin E coli related hemolytic uremic syndrome (STEC-HUS)</p> <ul style="list-style-type: none"> Treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive Treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive 		1
Ultomiris™ (ravulizumab-cwvz) Injection for intravenous use	<ul style="list-style-type: none"> Treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH) Treatment of adults and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) <p>Limitations of Use</p> <p>Ultomiris is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS)</p> <ul style="list-style-type: none"> Treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive 		2

See package insert for FDA prescribing information: <https://dailymed.nlm.nih.gov/dailymed/index.cfm>

CLINICAL RATIONALE

<p>Atypical Hemolytic Uremic Syndrome</p>	<p>Hemolytic uremic syndrome (HUS) is a syndrome characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. HUS typically develops in children, is preceded by bloody diarrhea, and responds well to supportive care. Typical HUS is caused by bacterial infection associated with Shiga toxin-producing Escherichia coli (STEC) or other bacteria and is called STEC-HUS. However, atypical HUS (aHUS) can develop at any age; 5%-10% of cases do not have prodromal diarrhea and have a poor prognosis.(12)</p> <p>The major pathogenesis of aHUS involves dysregulation of the complement system such as genetic abnormalities or autoantibodies, which are responsible for 60%-70% of cases. Mutation in the complement Factor H(CFH), Factor 1 (F1) is the most frequent cause of aHUS, followed by membrane cofactor protein (MCP), complement factor I (CFI), complement 3 (C3), complement Factor B (CFB), thrombomodulin (THBD), and others. Autoantibodies against CFH are detected in 6%-10% of cases of aHUS. Recently, complement-independent forms of aHUS, such as mutations in diacylglycerol kinase Epsilon (DGKE) and plasminogen (PLG) have been reported.(12)</p> <p>The two important differential diagnoses of aHUS in adults include TTP and secondary HUS. TTP is characterized by persistent thrombocytopenia and defect in ADAMTS13 activity, determined through fluorometric or chromogenic assay. ADAMTS13 assays are critical to differentiating between TTP and aHUS. Severe deficiency (less than 5-10% activity) is highly indicative of TTP. Secondary HUS may be considered in presence of autoimmune diseases, malignancies, hemopoietic stem cell or solid organ transplantation, malignant hypertension or use of drugs such as calcineurin inhibitors, gemcitabine, mitomycin, interferon, quinine, and cocaine. The treatment of secondary HUS is withdrawal of offending drug or treating triggering condition.(10)</p> <p>Since the ADAMTS13 testing often takes several days to complete and severe end-organ damage may occur, more rapid methods of diagnosis have been proposed. Patients with a severe ADAMTS13 deficiency typically present with blood creatinine less than 2.26 mg/dL and a platelet count less than 30,000/mm³; approximately 50% also show antinuclear antibodies. Diagnostic testing using blood creatinine, platelet count and presence of antinuclear antibodies had 98.1% specificity and 46.9% sensitivity.(10)</p> <p>Patients with aHUS require relatively comprehensive evaluation of the complement pathway. The evaluation should include:(10)</p> <p>Estimation of blood levels of C3, Factor H, I, and B, and anti-factor H antibodies</p> <p>Flow cytometry for MCP</p> <p>Sequencing, using a next generation approach for the following CFH, CD46, CFI, C3, CFB, THBD, CFHR1, CFHR3, CFHR5, and DGKE</p>
---	--

	<p>Results of the above investigations might not be available immediately however, therapy is initiated promptly. Therapy of aHUS is supportive, with attention to management of acute kidney injury and systemic complications. Although plasma exchange and plasma infusions (PE/PI) have been the standard of care for a HUS, they do not address the underlying cause of complement dysfunction.(10) A multi-center audit of plasma therapy for aHUS showed significant complications of central venous catheterization in 31% of patients. The median time to hematological remission was 11.5 days; 11% of patients did not enter hematological remission and 17% were dialysis dependent by day 33.(11) Because of unsatisfactory recovery, experts in most developed countries do not recommend the empiric use of PE/PI for patients with aHUS.</p> <p>Therapeutic strategies for aHUS have been based on resolution of dysregulation in the complement system. Previously, plasma therapy, including plasma infusion and exchange, was the first-line treatment option for patients with aHUS. However, the therapeutic efficiency of plasma therapy varies according to the causative genetic abnormalities of the alternative complement pathway or other pathways. Liver transplantation has been considered an alternative treatment option, although its utility is limited due to perioperative morbidities and donor shortage. Eculizumab, a monoclonal antibody to terminal C5, was introduced for the management of this debilitating disease and has shown superior outcomes; notably, it prevents organ damage and premature death more effectively than prior modalities. The long-acting C5 complement inhibitor, ravulizumab, received early approval by the Food and Drug Administration for the treatment of aHUS. This advance will improve the quality of life of aHUS patients.(12)</p>
Generalized Myasthenia Gravis	<p>Myasthenia gravis (MG) is a neuromuscular disorder primarily characterized by muscle weakness and muscle fatigue. Although the disorder usually becomes apparent during adulthood, symptom onset may occur at any age. The condition may be restricted to certain muscle groups, particularly those of the eyes (ocular myasthenia), or may become more generalized (generalized myasthenia gravis [gMG]), involving multiple muscle groups. Most individuals with myasthenia gravis develop weakness and drooping of the eyelids (ptosis); weakness of eye muscles, resulting in double vision (diplopia); and excessive muscle fatigue following activity. Additional features commonly include weakness of facial muscles; impaired speech (dysarthria); difficulties chewing and swallowing (dysphagia); and weakness of the upper arms and legs (proximal limb weakness). In addition, in about 10% of patients, affected individuals may develop potentially life-threatening complications due to severe involvement of muscles used during breathing (myasthenic crisis). Myasthenia gravis results from an abnormal immune reaction in which antibodies inappropriately attack and gradually injure certain receptors in muscles that receive nerve impulses (antibody-mediated autoimmune response).(13)</p> <p>The course of myasthenia gravis is highly variable. For example, the degree of muscle weakness may vary over hours, from day to day, or over weeks and months, tending to increase with repeated muscle use and to improve with rest. In addition, particularly during the first years after disease onset, some affected individuals may experience alternating periods in which symptoms temporarily subside or worsen. A short-term aggravation of symptoms may be triggered by a variety of factors, including infection, excessive physical activity, menstruation, and after delivery of a child.(13)</p> <p>Corticosteroids are a standard treatment for MG but may cause transient worsening within the first 2 weeks and patients should be monitored closely for this possibility. Because of this a MG consensus panel lists corticosteroids as one of many agents to avoid or use with caution in MG. A nonsteroidal immunosuppressive agent should be</p>

	<p>used initially in treating MG. Nonsteroidal immunosuppressive agents that can be used in MG include azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, and tacrolimus. For nonsteroidal immunosuppressive agents, once treatment goals have been achieved and maintained for 6 months to 2 years, the immunosuppressive dose should be tapered slowly to the minimal effective amount. Patients must be monitored for potential adverse effects and complications from immunosuppressive drugs. Changing to an alternative immunosuppressive agent should be considered if adverse effects and complications are medically significant or create undue hardship for the patient.(6)</p> <p>Plasma exchange and IVIg are appropriately used as short-term treatments in patients with MG with life-threatening signs such as respiratory insufficiency or dysphagia; in preparation for surgery in patients with significant bulbar dysfunction; when a rapid response to treatment is needed; when other treatments are insufficiently effective; and prior to beginning corticosteroids if deemed necessary to prevent or minimize exacerbations. The use of IVIg as maintenance therapy can be considered for patients with refractory MG or for those in whom immunosuppressive agents are contraindicated. Refractory MG is defined as post-intervention status is unchanged or worse after corticosteroids and at least 2 other immunosuppressive agents, used in adequate doses for an adequate duration, with persistent symptoms or side effects that limit functioning, as defined by the patient and physician.(6)</p> <p>Time to onset of effect and time to maximal effect varies between products. Azathioprine, mycophenolate mofetil, cyclosporine, and tacrolimus all take between 6 to 12 months to onset of effect and take 1 to 2 years to see maximal effect in MG. Rapid therapies such as plasmapheresis or IVIg therapy take approximately 1 week to time of onset of effect and 1 to 3 weeks for time to maximal effect.(16)</p> <p>Eculizumab is a more recent therapy for MG. Eculizumab prevents the formation of the membrane attack complex and reduces damage caused by complement-fixing AChR antibodies. Eculizumab should be considered in the treatment of severe, refractory, AChR-antibody positive generalize MG. Until further data becomes available to allow comparisons of cost and efficacy with other treatments, eculizumab should be considered after trials of other immunotherapies have been unsuccessful in meeting treatment goals.(6)</p> <p>Certain medications have established pharmacologic adverse effects on neuromuscular transmission. Use of these medications in a patient with MG can further reduce the effectiveness of neuromuscular transmission and cause increased clinical weakness. However, reported associations do not necessarily mean these medications should never be prescribed in MG. Clinical judgment and the risk-to-benefit ratio of the drug should be considered when it is deemed important for a patient’s treatment. Medications that can cause a significant increase in weakness in patients with MG include fluoroquinolones, botulinum toxin, ketolides (particularly telithromycin) and aminoglycoside antibiotics, beta blockers, macrolide antibiotics, procainamide, quinidine, quinine, and magnesium. A number of other medications may unmask or exacerbate MG, particularly the neuromuscular blocking agents used during anesthesia, which can lead to prolonged postoperative weakness and ventilator dependence.(6)</p>
<p>Paroxysmal Nocturnal Hemoglobinuria</p>	<p>Paroxysmal nocturnal hemoglobinuria (PNH) is a chronic, progressive, life-threatening, rare, multi-systemic disease developing as a result of somatic mutation of hematopoietic stem cells, and characterized by clonal, complement-mediated intravascular hemolysis. PNH is mainly a disease of adults with a median age of onset in the thirties. High Precision Flow Cytometry is the most useful and accepted diagnostic test to confirm the diagnosis of PNH. Flow cytometry is performed by incubating the patient’s peripheral blood cells with fluorescently-labeled monoclonal antibodies that bind to glycosylphosphatidylinositol (GPI) anchored proteins, which</p>

are reduced or absent on blood cells in PNH. Since different blood cell lineages display different combinations of GPI-linked proteins, and some proteins bind to cell surfaces via both GPI-linked and GPI-independent mechanisms, it is recommended that at least two independent flow cytometry reagents be used on at least two cell lineages (e.g., RBCs and WBCs) to establish the diagnosis of PNH.(7)

Lack of the complement inhibitor CD59 the red blood cells surface is mostly responsible for the clinical manifestations in PNH. These patients manifest with chronic intravascular hemolysis, paroxysmal flares of hemolysis and a propensity for thrombosis. Intravascular hemolysis leads to release of free hemoglobin (Hb) into the blood. Free hemoglobin, in turn, can cause various toxic effects, including hypercoagulability, changes in vascular tone from reduction of circulating nitric oxide and renal damage.(15)

Extravascular hemolysis also occurs in patients with PNH because C3 fragments that are not destroyed by the membrane attack complex (MAC) intravascularly can accumulate on the GPI-negative red blood cell (lacking CD55) surface and these fragments opsonize the red blood cells, causing reticuloendothelial destruction in the liver and spleen.(15)

The main clinical situations or diseases that should be considered in the differential diagnosis of PNH are as follows:(15)

Coombs-negative hemolytic anemia (e.g., hemoglobinopathies, hereditary spherocytosis), microangiopathic hemolytic anemias, drug- or toxin-induced hemolysis/anemias, disseminated intravascular coagulation, and autoimmune hemolysis

Venous thrombosis in atypical sites, including myeloproliferative disorders; solid tumors associated with hypercoagulability; extrinsic compression of vessels, and; inherited/acquired thrombophilias

Anemia and/or other cytopenias related to bone marrow failure syndrome (e.g., aplastic anemia, MDS)

PNH is classified into three different categories:(15)

Classic PNH (PNH with clinical and laboratory findings of intravascular hemolysis without any evidence of bone marrow deficiency)

PNH in the setting of another specified bone marrow disorder (evidence of hemolysis, as well as another specified bone marrow disorder [e.g., aplastic anemia, MDS])

Subclinical PNH (patients with a small population of PNH cells and no clinical or laboratory evidence of hemolysis or thrombosis)

Patients with PNH have a median survival of ten years after diagnosis. The approach to therapy depends on the severity of symptoms and the degree of hemolysis.

	Supportive treatment including folic acid, iron replacement and transfusion ± Soliris is considered standard of care.(
Neuromyelitis Optica Spectrum Disorder	<p>Neuromyelitis optica spectrum disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis). Classically, it was felt to be a monophasic illness, consisting of episodes of inflammation of one or both optic nerves and the spinal cord over a short period of time (days or weeks) but, after the initial episode, no recurrence. It is now recognized that most patients satisfying current criteria for NMOSD experience repeated attacks separated by periods of remission. The interval between attacks may be weeks, months or years.(5)</p> <p>Early in the course of the disease, it may be difficult to distinguish between NMOSD and multiple sclerosis because both may cause optic neuritis and myelitis as symptoms. However, the optic neuritis and myelitis tend to be more severe in NMOSD; the brain MRI is more commonly normal, and the spinal fluid analysis does not usually show oligoclonal bands in NMOSD, which are features that help distinguish it from MS.(5)</p> <p>NMOSD can be AQP4 antibody positive or negative. The diagnostic criteria for NMOSD with AQP4 positive diagnosis are as follows: at least 1 core clinical characteristic, a positive test for AQP4-IgG, and exclusion of alternative diagnoses. The core clinical characteristics are as follows:(8)</p> <p>Optic neuritis</p> <p>Acute myelitis</p> <p>Area postrema syndrome: episode of otherwise unexplained hiccups or nausea and vomiting</p> <p>Acute brainstem syndrome</p> <p>Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions</p> <p>Symptomatic cerebral syndrome with NMOSD-typical brain lesions</p> <p>An international consensus panel reached several conclusions in addition to the above criteria to establish a NMOSD diagnosis. First, at least 1 discrete clinical attack of CNS symptoms must occur to establish NMOSD diagnosis. Although asymptomatic AQP4-IgG seropositive status may exist for years before clinical NMOSD presentation, the natural history of asymptomatic seropositivity is poorly understood. Second, NMOSD diagnosis is not warranted in asymptomatic patients with NMOSD-compatible MRI lesions because the expected clinical course in such individuals is unknown. Third, no clinical characteristic is pathognomonic of NMOSD. Accordingly, a single clinical manifestation is not diagnostic when AQP4-IgG is not detected. Finally, no single characteristic is exclusionary, but some are considered red flags that signal the possibility of alternative diagnoses. The main clinical red flags concern the temporal course of the syndrome rather than the actual manifestations. Most notably, a gradually progressive course of neurologic worsening over months to years is very uncommon (1%–2%) in NMOSD. However, after</p>

	<p>thorough investigation for potential competing disorders, the weight of evidence may justify NMOSD diagnosis despite presence of 1 or more red flags.(8)</p> <p>Treatment strategies for attack prevention in NMOSD and MS differ. Some MS immunotherapies appear to aggravate NMOSD, indicating an imperative for early, accurate diagnosis. Patients with NMOSD who are AQP4-IgG seropositive should be assumed to be at risk for relapse indefinitely and preventive treatment should be considered.(8) Azathioprine and mycophenolate mofetil have been used off label to prevent NMOSD attacks for decades. Their efficacy in NMOSD has been demonstrated in several retrospective studies and case series. In recent years, their use in NMOSD has declined in favor of rituximab owing to their comparative lower efficacy as demonstrated in multiple retrospective studies.(14)</p> <p>Rituximab is one of the most commonly used off-label preventative therapies in NMOSD. Rituximab is a monoclonal antibody (MAB) against CD20-positive B-Cells with include pre B-cell, immature B-cell, and memory B-cell lineage but not plasmablasts or plasma cells. Its exact mechanism of action in NMOSD is unknown but is hypothesized to involve reduction of pathogenic antibody production, dampening of pro-inflammatory cytokines, and decreasing B-cell dependent antigen presentation to T-cells.(14)</p> <p>Eculizumab, ibalizumab, and satralizumab are FDA approved therapies that can be used as add on or monotherapy for NMOSD.</p> <p>Disability in NMO is a direct consequence of the relapse. Spontaneous gradual progression of disability like in MS is very rare in NMO. Thus, NMO relapses are a clinically relevant measure. Amongst secondary end points, disability is very important. The main categories are spinal cord/ brainstem related, motor (weakness, spasticity), sensory (numbness and pain), bladder, bowel, sexual function, and vision. EDSS is suitable and well validated in MS research, but cerebellar and cerebral functional scales are not really applicable in NMO, as cognitive and cerebellar dysfunction is limited in NMO. The Optic Spinal Impairment Scale is derived and modified from EDSS. There are no formal psychometrics supporting the scale and it is not widely used. There are numerous vision specific scales, but none are specific for optic neuritis.(9)</p>
Soliris Efficacy(1)	<p>aHUS</p> <p>Soliris inhibits terminal complement-mediated intravascular hemolysis in patients with atypical hemolytic uremic syndrome (aHUS).</p> <p>The efficacy of Soliris for the treatment of patients with aHUS was evaluated in 3 clinical studies including 2 single-arm, open label prospective studies in adults and adolescents and one retrospective study in pediatric patients 2 months to 17 years of age with the disease. The first prospective study (n=17) included patients with progressing thrombotic microangiopathy despite plasma therapy, and the second study (n=20) included patients who were receiving chronic plasma exchange or infusion but generally did not have evidence of ongoing thrombotic microangiopathy. In all three trials the endpoints evaluated were platelet count change from baseline, hematologic normalization (maintenance of normal platelet counts and LDH levels for at least 4 weeks), complete TMA response (hematologic normalization plus at least a</p>

25% reduction in serum creatinine for a minimum of 4 weeks), TMA-event free status (absence for at least 12 weeks of a decrease in platelet count of greater than 25% from baseline, plasma exchange or plasma infusion and new dialysis requirement), and daily TMA intervention rate (number of plasma exchange or plasma infusion interventions (PE/PI) and the number of new dialysis required per patient per day).

Study 1 enrolled 17 patients with aHUS who were refractory to plasma therapy (PE/PI). Patients were treated for a minimum of 26 weeks (mean was 38 weeks). Soliris reduced signs of complement-mediated TMA activity, as shown by an increase in mean platelet counts from $109 \pm 32 \times 10^9/L$ at baseline to $169 \pm 72 \times 10^9/L$ by one week with the effect maintained through 26 weeks. Hematologic normalization (platelet counts and serum LDH concentrations) and complete TMA response were maintained by all responders. Renal function improved as indicated by increases in the eGFR from baseline and requirements for dialysis were reduced. Response to Soliris was similar in patients with or without complement gene mutations.

Study 2 enrolled 20 patients with aHUS who were sensitive to plasma therapy (PE/PI). Patients were treated for a minimum of 26 weeks (mean was 40 weeks). Soliris reduced signs of complement-mediated TMA in this study as well. Platelet counts were maintained at normal levels despite elimination of PE/PI. The mean platelet count was $228 \pm 78 \times 10^9/L$ at baseline and $233 \pm 69 \times 10^9/L$ at week 26. Hematologic normalization (platelet counts and serum LDH concentrations) and complete TMA response were maintained by all responders. Renal function was maintained during Soliris therapy.

Study 3 (retrospective study) included 19 pediatric patients (2 months of age to 17 years). The median duration of Soliris therapy was 16 to 38 weeks depending on the age of the patient. Efficacy results were consistent with the results of Study 1 and 2. Soliris reduced signs of complement-mediated TMA, as shown by an increase in mean platelet counts of $171 \pm 83 \times 10^9/L$ at baseline to $233 \pm 109 \times 10^9/L$ one week after therapy with the effect maintained through 26 weeks (mean platelet count $254 \pm 79 \times 10^9/L$).

PNH

Similar to aHUS, Soliris inhibits terminal complement-mediated intravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) patients. Soliris improves symptoms of PNH by reducing hemolysis, stabilizing hemoglobin concentrations, and decreasing the need for RBC transfusions.

One randomized, double-blind, placebo-controlled 26-week efficacy study (TRIUMPH) evaluated Soliris in the treatment of PNH (n=87). Patients with PNH who had received at least 4 red blood cell transfusions during the 12 months prior to study entry were randomized to receive Soliris or placebo for 26 weeks. Patients were permitted to continue supportive therapies for PNH such as anticoagulants and systemic corticosteroids. Primary endpoints were stabilization of hemoglobin above the level required for transfusion and number of packed red blood cells transfused during the study period. Secondary efficacy measures included hemolysis, change in

the level of fatigue as measured by FACIT-fatigue score, and proportion of patients with transfusion independence. Stabilization of hemoglobin levels occurred in 49% of Soliris treated patients compared to 0% in the placebo group (p less than 0.001). The median number of packed red blood cells infused was zero in the Soliris group compared to ten in the placebo group (p less than 0.001). Transfusion independence was achieved by 51% of patients treated with Soliris compared to zero for placebo (p less than 0.001). Fatigue scores were improved with Soliris (+6.4 points) versus placebo (-4 points) (p less than 0.001). Hemolysis was also reduced with Soliris therapy compared to placebo (p less than 0.001).

Generalized Myasthenia Gravis

The precise mechanism by which Soliris exerts its therapeutic effect in generalized myasthenia gravis (gMG) patients is unknown, but is presumed to involve reduction of terminal complement complex C5b-9 deposition at the neuromuscular junction.

A 26-week, phase 3, randomized, double-blind, parallel-group, placebo-controlled, multicenter study (REGAIN) was conducted to determine the safety and efficacy of Soliris in anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis. Eligible patients (N=125) were at least 18 years old; had a positive serological test for anti-acetylcholine receptor antibodies; had a Myasthenia Gravis-Activities of Daily Living (MG-ADL) score of 6 or more; had a Myasthenia Gravis Foundation of America (MGFA) clinical classification class II-IV disease; had vaccination against Neisseria meningitides; and had previously failed treatment with at least 2 immunosuppressive therapies or one immunosuppressive therapy and chronic intravenous immunoglobulin or plasmapheresis/plasma exchange (given at least four times per year, for 12 months without symptom control). The primary efficacy endpoint was the change from baseline to week 26 in MG-ADL total score, as measured by the worst-rank ANCOVA. The primary analysis showed no significant difference between Soliris and placebo (least squares mean rank 56.6 [SEM 4.5] vs 68.3 [4.5]; rank-based treatment difference -11.7, 95% CI -24.3 to 0.96; p=0.0698). However, there was a statistically significant difference in the change in MG-ADL score from baseline to week 26 between Soliris and placebo in a pre-specified sensitivity repeated-measures model analysis with immunosuppressive treatments as covariates, (least squares mean -4.2 (SEM 0.49) vs. -2.3 (0.48); least squares mean difference of change in score with Soliris relative to placebo -1.9, 95% CI -3.3 to -0.6; p=0.006).(1) The REGAIN trial discussion notes, “using the repeated-measures analyses, the benefit of Soliris compared with placebo occurred within the first 4 weeks of treatment, with most of the effect achieved by 12 weeks.”

MGFA Clinical Classification(4)

Class	Features
I	Any ocular muscle weakness; may have weakness of eye closure; All other muscles are normal
II	Mild weakness affecting muscles other than the ocular muscles; may also have ocular muscle weakness of any severity
IIa	Predominantly affecting limb, axial muscles, or both. May also have lesser involvement of oropharyngeal muscles.
IIb	Predominantly affecting oropharyngeal, respiratory muscles, or both. May also have lesser or equal involvement of limb, axial muscles, or both.

III	Moderate weakness affecting muscles other than the ocular muscles; may also have ocular muscle weakness of any severity
IIIa	Predominantly affecting limb, axial muscles, or both. May also have lesser involvement of oropharyngeal muscles.
IIIb	Predominantly affecting oropharyngeal, respiratory muscles, or both. May also have lesser or equal involvement of limb, axial muscles, or both.
IV	severe weakness affecting muscles other than the ocular muscles; may also have ocular muscle weakness of any severity
IVa	Predominantly affecting limb, axial muscles, or both. May also have lesser involvement of oropharyngeal muscles.
IVb	Predominantly affecting oropharyngeal, respiratory muscles, or both. May also have lesser or equal involvement of limb, axial muscles, or both.
V	Intubation with or without mechanical ventilation (exception: intubation for routine perioperative management). The use of a feeding tube without intubation places a patient in class IVb.

NMOSD

The efficacy of Soliris for the treatment of NMOSD was established in NMOSD Study 1 (NCT01892345), a randomized, double-blind, placebo-controlled trial that enrolled 143 patients (96 patients were randomized to receive Solaris treatment and 47 were randomized to receive placebo) with NMOSD who were anti-AQP4 antibody positive and met the following criteria at screening:

History of at least 2 relapses in last 12 months or 3 relapses in the last 24 months, with at least 1 relapse in the 12 months prior to screening

Expanded Disability Status Scale (EDSS) score less than or equal to 7 (consistent with the presence of at least limited ambulation with aid)

If on immunosuppressive therapy, on a stable dose regimen

The use of concurrent corticosteroids was limited to 20 mg per day or less

Patients were excluded if they had been treated with rituximab or mitoxantrone within 3 months or with IVIg within 3 weeks prior to screening

The primary endpoint for NMOSD Study 1 was the time to the first adjudicated on-trial relapse. The time to the first adjudicated on-trial relapse was significantly longer in Soliris-treated patients compared to placebo-treated patients (relative risk reduction 94%; hazard ratio 0.058; p less than 0.0001). Soliris-treated patients experienced similar improvement in time to first adjudicated on-trial relapse with or without concomitant treatment. Soliris-treated patients had a 96% relative reduction in the adjudicated on-trial annualized relapse rate (ARR) compared to patients on placebo.

	<p>Compared to placebo-treated patients, Soliris-treated patients had reduced annualized rates of hospitalizations (0.04 for Soliris versus 0.31 for placebo), of corticosteroid administrations to treat acute relapses (0.07 for Soliris versus 0.42 for placebo), and of plasma exchange treatments (0.02 for Soliris versus 0.19 for placebo).</p>
<p>Ultomiris Efficacy(2)</p>	<p>Ultomiris (ravulizumab-cwvz), is a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex.</p> <p>PNH</p> <p>The safety and efficacy of Ultomiris in patients with PNH was assessed in two open-label, randomized, active-controlled, non-inferiority Phase 3 studies: PNH Study 301 and PNH Study 302. Study 301 enrolled patients with PNH who were complement inhibitor naïve and had active hemolysis. Study 302 enrolled patients with PNH who were clinically stable after having been treated with eculizumab for at least the past 6 months.</p> <p>PNH Study 301 was a 26-week study that enrolled 246 patients. Efficacy was established based upon transfusion avoidance and hemolysis as directly measured by normalization of LDH levels. Transfusion avoidance was defined as patients who did not receive a transfusion and not meet the protocol specified guidelines for transfusion from baseline up to Day 183. Supportive efficacy data included the percent change from baseline in LDH levels, the proportion of patients with breakthrough hemolysis defined as at least one new or worsening symptom or sign of intravascular hemolysis in the presence of elevated LDH greater than or equal to 2 × ULN, after prior LDH reduction to less than 1.5 × ULN on therapy and the proportion of patients with stabilized hemoglobin. Non-inferiority of Ultomiris to eculizumab was demonstrated across endpoints in the complement inhibitor naïve treatment population.</p> <p>PNH Study 302 was a 26-week study that enrolled 195 patients. Efficacy was established based on hemolysis as measured by LDH percent change from baseline to Day 183 and supportive efficacy data was transfusion avoidance, proportion of patients with stabilized hemoglobin, and the proportion of patients with breakthrough hemolysis through Day 183. Non-inferiority of Ultomiris to eculizumab was demonstrated across endpoints in the patients with PNH previously treated with eculizumab.</p> <p>aHUS</p> <p>The efficacy of Ultomiris in patient with atypical hemolytic uremic syndrome (aHUS) was assessed in 2 open-label, single-arm studies. Study ALXN1210-aHUS-311 enrolled adult patients who displayed signs of thrombotic microangiopathy (TMA) and Study ALXN1210-aHUS-312 enrolled pediatric patients who displayed signs of TMA.</p> <p>Study ALXN1210-aHUS-311 a total of 56 patients with aHUS were evaluated for efficacy. The efficacy evaluation was based on Complete TMS response during the 26-week initial evaluation period, as evidenced by normalization of hematological</p>

	<p>parameters (platelet count and LDH) and greater than or equal to 25% improvement in serum creatinine from baseline. Complete TMA response was observed in 30 of the 56 patients (34%) during the 26-week initial evaluation period.</p> <p>Study ALXN1210-aHUS-312 is a 26-week ongoing, multicenter, single-arm, study conducted in 14 patients with documented a-HUS. Efficacy evaluation was based upon complete TMA response during the 26-week initial evaluation period, as evidenced by normalization of hematological parameters (platelet count and LDA) and greater than or equal to 25% improvement in serum creatinine from baseline. Complete TMA response was observed in 10 of the 14 patients (71%) during the 26-week initial evaluation period.</p> <p>MG</p> <p>The efficacy of Ultomiris for the treatment of gMG was demonstrated in a randomized, double-blind, placebo-controlled, multicenter study (ALXN1210-MG-306; NCT03920293). Patients with gMG with a positive serologic test for anti-AChR antibodies, Myasthenia Gravis Foundation of America (MGFA) clinical classification class II to IV, and Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score greater than or equal to 6 were enrolled.</p> <p>The primary efficacy endpoint was a comparison of the change from baseline between treatment groups in the MG-ADL total score at Week 26. The secondary endpoints, also assessed from baseline to Week 26, included the change in the Quantitative MG total score (QMG), the proportion of patients with improvements of at least 5 and 3 points in the QMG and MG-ADL total scores, respectively.</p> <p>Treatment with Ultomiris demonstrated a statistically significant change in the MG-ADL and QMG total scores from baseline at Week 26 as compared to placebo. MG-ADL LS Mean was -1.4 for placebo group and -3.1 for the Ultomiris group. QMG LS Mean was -0.8 for placebo group and -2.8 for the Ultomiris group (both MG-ADL and QMG score changes has p value less than 0.001).</p>
Safety(1-2)	<ul style="list-style-type: none"> Soliris (eculizumab) and Ultomiris (ravulizumab-cwvz) are available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Both contain a boxed warning for an increased risk of meningococcal infections. All patients without a history for meningococcal vaccination should receive the vaccine at least two weeks prior to receiving the first dose of Soliris or Ultomiris. <p>Soliris (eculizumab) and Ultomiris (ravulizumab-cwvz) are contraindicated in:</p> <ul style="list-style-type: none"> Patients with unresolved serious <i>Neisseria meningitidis</i> infection Patients who are not currently vaccinated against <i>Neisseria meningitidis</i>, unless the risks of delaying treatment outweigh the risks of developing a meningococcal infection.

REFERENCES

Number	Reference
1	Soliris prescribing information. Alexion. November 2020.
2	Ultomiris prescribing information. Alexion. April 2022.
3	National Institute of Neurological Disorders and Stroke. Myasthenia Gravis Fact Sheet. NIH Publication No. 17-768. July 2018.
4	Myasthenia Gravis Foundation of America. Myasthenia Gravis: A Manual for the Health Care Provider (PDF). 2010.
5	National organization for Rare disorders (NORD). Rare Disease Database. Neuromyelitis Optica Spectrum Disorder.
6	Narayanaswami P, Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis. 2020 Update. Neurology volume 96; Number 3. January 19, 2021.
7	Sahin Fahri, Meltem Akay O, Ayer M, et al. Pesg PNH diagnosis, follow-up and treatment guidelines. Am J Blood Res. 2016; 6(2): 19-27.
8	Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14; 85(2): 177-189.
9	Regulatory workshop on clinical trials designs in neuromyelitis optica spectrum disorders (NMOSD). 16 June 2015.
10	Rupesh R, Krishnappa V, Blaha T, et al. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. Therapeutic Apheresis and Dialysis 2019; 23(1):4-21.
11	Johnson S, Stojanovic J, Ariceta G, et al. An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatr Nephrol 2014;29:1967-78.
11	Johnson S, Stojanovic J, Ariceta G, et al. An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatr Nephrol 2014;29:1967-78.
12	Lee H, Kang E, Gyun Kang H, et al. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med 2020;35:25-40.
12	Lee H, Kang E, Gyun Kang H, et al. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med 2020;35:25-40.
13	National Organization for Rare Disorders (NORD). Rare Disease Database. Myasthenia Gravis.
14	Abboud H, Zheng C, Kar I, Chen CK, Sau C, Serra A. Current and emerging therapeutics for neuromyelitis optica spectrum disorder: Relevance to the COVID-19 pandemic. Mult Scler Relat Disord. 2020;44:102249. doi:10.1016/j.msard.2020.102249.
14	Abboud H, Zheng C, Kar I, Chen CK, Sau C, Serra A. Current and emerging therapeutics for neuromyelitis optica spectrum disorder: Relevance to the COVID-19 pandemic. Mult Scler Relat Disord. 2020;44:102249. doi:10.1016/j.msard.2020.102249.
15	Rodolfo D. Caçado, Aderson da Silva Araújo, Alex Freire Sandes, Celso Arrais, Clarisse Lopes de Castro Lobo, Maria Stella Figueiredo, Sandra Fátima Menosi Gualandro, Sara Teresinha Olalla Saad, Fernando Ferreira Costa. Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. Hematology, Transfusion and Cell Therap. 2020.
16	Bird SJ. UpToDate. Overview of the treatment of myasthenia gravis. Literature review current through January 2022.

POLICY AGENT SUMMARY – MEDICAL PRIOR AUTHORIZATION

HCPC Codes	Agent Names	Strength	Targeted MSC	Available MSC	Preferred Status	Effective Date
J1300	SOLIRIS (eculizumab iv soln)	300 MG/30ML	M ; N ; O ; Y	N		
J1303	ULTOMIRIS (ravulizumab-cwvz iv soln)	300 MG/30ML	M ; N ; O ; Y	N		
J1303	ULTOMIRIS (ravulizumab-cwvz iv soln)	300 MG/3ML	M ; N ; O ; Y	N		
J1303	ULTOMIRIS (ravulizumab-cwvz iv soln)	1100 MG/11ML	M ; N ; O ; Y	N		

CLIENT SUMMARY – PRIOR AUTHORIZATION

Agent Names	Strength	Client Formulary
SOLIRIS (eculizumab iv soln)	300 MG/30ML	Commercial ; HIM
ULTOMIRIS (ravulizumab-cwvz iv soln)	300 MG/30ML	Commercial ; HIM
ULTOMIRIS (ravulizumab-cwvz iv soln)	300 MG/3ML	Commercial ; HIM
ULTOMIRIS (ravulizumab-cwvz iv soln)	1100 MG/11ML	Commercial ; HIM

PRIOR AUTHORIZATION CLINICAL CRITERIA FOR APPROVAL

Module	Clinical Criteria for Approval
Soliris	<p>Soliris Initial Evaluation</p> <p>Soliris (eculizumab) will be approved when ALL of the following are met:</p> <ol style="list-style-type: none"> 1. ONE of the following: <ol style="list-style-type: none"> A. The patient has a diagnosis of generalized Myasthenia Gravis (gMG) AND ALL of the following: <ol style="list-style-type: none"> 1. The patient has a positive serological test for anti-AChR antibodies (lab test must be submitted) AND 2. The patient has a Myasthenia Gravis Foundation of America (MGFA) clinical classification class of II-IV AND 3. The patient has a MG-Activities of Daily Living total score of greater than or equal to 6 AND 4. ONE of the following: <ol style="list-style-type: none"> A. The prescriber has assessed the patient’s current medications and discontinued any medications known to exacerbate myasthenia gravis (e.g., beta blockers, procainamide, quinidine, magnesium, anti-programmed death receptor-1 monoclonal antibodies, hydroxychloroquine, aminoglycosides) OR B. The prescriber has provided clinical rationale indicating that discontinuation of the offending agent is not clinically appropriate AND 5. ONE of the following: <ol style="list-style-type: none"> A. The patient has tried and had an inadequate response to at least 2 immunosuppressive therapies (e.g., azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate, cyclophosphamide) for at least a 1-year total trial (either combination or monotherapy) OR B. The patient has an intolerance or hypersensitivity to at least 2 immunosuppressive therapies OR

Module	Clinical Criteria for Approval
	<p>C. The patient has tried and had an inadequate response to treatment to at least 1 immunosuppressive therapy (e.g., azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate, cyclophosphamide) for at least a 1-year total trial AND ONE of the following:</p> <ol style="list-style-type: none"> 1. The patient required chronic intravenous immunoglobulin (IVIG) (i.e., at least every 3 months over 12 months without symptom control) OR 2. The patient required chronic plasmapheresis/plasma exchange (i.e., at least every 3 months over 12 months without symptom control) OR <p>D. The patient has an intolerance or hypersensitivity to at least 1 immunosuppressant AND plasmapheresis/plasma exchange OR</p> <p>E. The patient has an FDA labeled contraindication to ALL immunosuppressive therapies and plasmapheresis/plasma exchange AND</p> <p>6. ONE of the following:</p> <ol style="list-style-type: none"> A. The patient has tried and had an inadequate response to Ultomiris (ravulizumab-cwvz) or Vyvgart (efgartigimod) OR B. The patient has an intolerance or hypersensitivity to Ultomiris (ravulizumab-cwvz) or Vyvgart (efgartigimod) OR C. The patient has an FDA labeled contraindication to BOTH Ultomiris (ravulizumab-cwvz) and Vyvgart (efgartigimod) OR <p>B. The patient has a diagnosis of Paroxysmal Nocturnal Hemoglobinuria (PNH) AND ALL of the following:</p> <ol style="list-style-type: none"> 1. The diagnosis was confirmed by flow cytometry with at least 2 independent flow cytometry reagents on at least 2 cell lineages (e.g., RBCs and WBCs) demonstrating that the patient's peripheral blood cells are deficient in glycosylphosphatidylinositol (GPI) – linked proteins (lab tests required) AND 2. ONE of the following: <ol style="list-style-type: none"> A. The patient has tried and had an inadequate response to BOTH Empaveli (pegcetacoplan) AND Ultomiris (ravulizumab-cwvz) OR B. The patient has an intolerance or hypersensitivity to BOTH Empaveli (pegcetacoplan) AND Ultomiris (ravulizumab-cwvz) OR C. The patient has an FDA labeled contraindication to BOTH Empaveli (pegcetacoplan) AND Ultomiris (ravulizumab-cwvz) OR D. The patient is currently being treated with the requested agent (medical records including last date of infusion required) AND 3. The patient will NOT be using the requested agent in combination with Empaveli (pegcetacoplan) for the requested indication OR <p>C. The patient has a diagnosis of atypical Hemolytic Uremic Syndrome (aHUS) AND ALL of the following:</p> <ol style="list-style-type: none"> 1. The diagnosis was confirmed by ONE of the following: (medical records required) <ol style="list-style-type: none"> A. Genetic mutation (e.g., <i>CFH</i>, <i>CD46</i>, <i>CFI</i>, <i>C3</i>, <i>CFB</i>, <i>THBD</i>, <i>CFHR1</i>, <i>CFHR3</i>, <i>CFHR5</i>) OR B. Antibodies to complement factors OR C. A differential diagnosis of complement-mediated HUS has been demonstrated [i.e., screening for Shiga toxin-producing <i>E. coli</i> (STEC) for STEC-HUS, pneumococcal culture of blood/sputum/cerebrospinal or pleural fluid for pneumococcal-associated HUS, ADAMTS13 less than 10% activity for thrombotic thrombocytopenic purpura (TTP), screening for defective cobalamin metabolism] AND 2. The patient is negative for Shiga toxin-producing <i>E. coli</i> (STEC) AND 3. ONE of the following: <ol style="list-style-type: none"> A. The patient has tried and had an inadequate response to Ultomiris (ravulizumab-cwvz) OR B. The patient has an intolerance or hypersensitivity to Ultomiris (ravulizumab-cwvz) OR

Module	Clinical Criteria for Approval
	<p>C. The patient has an FDA labeled contraindication to Ultomiris (ravulizumab-cwvz) OR</p> <p>D. The patient has a diagnosis of neuromyelitis optica spectrum disorder (NMOSD) AND ALL of the following:</p> <ol style="list-style-type: none"> 1. The patient is anti-aquaporin-4 (AQP4) antibody positive AND 2. The diagnosis was confirmed by at least ONE of the following: <ol style="list-style-type: none"> A. Optic neuritis OR B. Acute myelitis OR C. Area postrema syndrome: episode of otherwise unexplained hiccups or nausea and vomiting OR D. Acute brainstem syndrome OR E. Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions OR F. Symptomatic cerebral syndrome with NMOSD-typical brain lesions AND 3. The patient has had at least 1 discrete clinical attack of CNS symptoms AND 4. Alternative diagnoses (e.g., multiple sclerosis, ischemic optic neuropathy) have been ruled out AND 5. ONE of the following: <ol style="list-style-type: none"> A. The patient has tried and had an inadequate response to Enspryng (satralizumab-mwge) OR Uplizna (inebilizumab-cdon) OR B. The patient has an intolerance or hypersensitivity to Enspryng (satralizumab-mwge) OR Uplizna (inebilizumab-cdon) OR C. The patient has an FDA labeled contraindication to BOTH Enspryng (satralizumab-mwge) AND Uplizna (inebilizumab-cdon) OR D. The patient has severe disease, and the prescriber has determined that BOTH Enspryng (satralizumab-mwge) AND Uplizna (inebilizumab-cdon) would not be clinically appropriate for the patient OR E. The patient is currently using the requested agent (medical records including last date of infusion required) AND 6. The patient will NOT be using the requested agent in combination with Enspryng, rituximab, or Uplizna for the requested indication OR <p>E. The patient has another FDA approved indication for the requested agent AND</p> <ol style="list-style-type: none"> 2. ONE of the following: <ol style="list-style-type: none"> A. The patient's age is within FDA labeling for the requested indication for the requested agent OR B. The prescriber has provided information supporting the use of the requested agent for the patient's age for the requested indication AND 3. The prescriber is a specialist in the area of the patient's diagnosis or the prescriber has consulted with a specialist in the area of the patient's diagnosis AND 4. The patient will NOT be using the requested agent in combination with Ultomiris AND 5. The patient does NOT have any FDA labeled contraindications to the requested agent AND 6. The requested quantity (dose) is within FDA labeled dosing for the requested indication <p>Length of Approval: Generalized Myasthenia Gravis: 3 months</p> <p>All other diagnoses: 6 months</p> <p>Soliris Renewal Evaluation</p> <p>Soliris (eculizumab) will be approved when ALL of the following are met:</p>

Module	Clinical Criteria for Approval
	<ol style="list-style-type: none"> 1. The patient was previously approved for the requested agent through the plan's Medical Drug Review process AND 2. ONE of the following: <ol style="list-style-type: none"> A. The patient has a diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) AND BOTH of the following: <ol style="list-style-type: none"> 1. The prescriber has provided information that the patient has had clinical benefit with the requested agent (e.g., decreased requirement for RBC transfusions, stabilization/improvement of hemoglobin, reduction of lactate dehydrogenase [LDH]) (medical records required) AND 2. The patient will NOT be using the requested agent in combination with Empaveli (pegcetacoplan) for the requested indication OR B. The patient has a diagnosis of atypical hemolytic uremic syndrome (aHUS) AND BOTH of the following: <ol style="list-style-type: none"> 1. The prescriber has provided information that the patient has had clinical benefit with the requested agent (e.g., improved platelet count, reduction of lactate dehydrogenase [LDH], stabilization/improvement of renal function) (medical records required) AND 2. ONE of the following: <ol style="list-style-type: none"> A. The patient has tried and had an inadequate response to Ultomiris (ravulizumab-cwvz) OR B. The patient has an intolerance or hypersensitivity to Ultomiris (ravulizumab-cwvz) OR C. The patient has an FDA labeled contraindication to Ultomiris (ravulizumab-cwvz) OR C. The patient has a diagnosis of generalized myasthenia gravis (gMG) AND BOTH of the following: <ol style="list-style-type: none"> 1. The prescriber has provided information that the patient has had clinical benefit with the requested agent (e.g., improved MG-ADL total score, improved quantitative myasthenia gravis total score) (medical records required) AND 2. ONE of the following: <ol style="list-style-type: none"> A. The patient has tried and had an inadequate response to Ultomiris (ravulizumab-cwvz or Vyvgart (efgartigimod) OR B. The patient has an intolerance or hypersensitivity to Ultomiris (ravulizumab-cwvz) or Vyvgart (efgartigimod) OR C. The patient has an FDA labeled contraindication to BOTH Ultomiris (ravulizumab-cwvz) and Vyvgart (efgartigimod) OR D. The patient has a diagnosis of neuromyelitis optica spectrum disorder (NMOSD) AND BOTH of the following: <ol style="list-style-type: none"> 1. The prescriber has provided information that the patient has had clinical benefit with the requested agent (e.g., decreased relapses, improvement or stabilization of vision or paralysis) (medical records required) AND 2. The patient will NOT be using the requested agent in combination with Enspryng, rituximab, or Uplizna for the requested indication OR E. The patient has another FDA approved indication for the requested agent AND the prescriber has provided information that the patient has had clinical benefit with the requested agent (e.g., improvement or stabilization of symptoms) (medical records required) AND 3. The prescriber is a specialist in the area of the patient's diagnosis or the prescriber has consulted with a specialist in the area of the patient's diagnosis AND 4. The patient will NOT be using the requested agent in combination with Ultomiris AND 5. The patient does not have any FDA labeled contraindications to the requested agent AND 6. The requested dose is within FDA labeled dosing for the requested indication <p>Length of Approval: 12 months</p>
Ultomiris	<p>Ultomiris Initial Evaluation</p> <p>Ultomiris (ravulizumab-cwvz) will be approved when ALL of the following are met:</p> <ol style="list-style-type: none"> 1. One of the following:

Module	Clinical Criteria for Approval
	<p>A. The patient has a diagnosis of Paroxysmal Nocturnal Hemoglobinuria (PNH) AND BOTH of the following:</p> <ol style="list-style-type: none"> 1. The diagnosis was confirmed by flow cytometry with at least 2 independent flow cytometry reagents on at least 2 cell lineages (e.g., RBCs and WBCs) demonstrating that the patient's peripheral blood cells are deficient in glycosylphosphatidylinositol (GPI)-linked proteins (lab tests required) AND 2. The patient will NOT be using the requested agent in combination with Empaveli (pegcetacoplan) OR <p>B. The patient has a diagnosis of atypical Hemolytic Uremic Syndrome (aHUS) AND BOTH of the following:</p> <ol style="list-style-type: none"> 1. The diagnosis has been confirmed by ONE of the following: (medical records required) <ol style="list-style-type: none"> A. Genetic mutation (e.g., <i>CFH</i>, <i>CD46</i>, <i>CFI</i>, <i>C3</i>, <i>CFB</i>, <i>THBD</i>, <i>CFHR1</i>, <i>CFHR3</i>, <i>CFHR5</i>) OR B. Antibodies to complement factors OR C. A differential diagnosis of complement-mediated HUS has been demonstrated [i.e., screening for Shiga toxin-producing <i>E. coli</i> (STEC) for STEC-HUS, pneumococcal culture of blood/sputum/cerebrospinal or pleural fluid for pneumococcal-associated HUS, ADAMTS13 less than 10% activity for thrombotic thrombocytopenic purpura (TTP), screening for defective cobalamin metabolism] AND 2. The patient is negative for Shiga toxin-producing <i>E. coli</i> (STEC) OR <p>C. The patient has a diagnosis of generalized Myasthenia Gravis (gMG) AND ALL of the following:</p> <ol style="list-style-type: none"> 1. The patient has a positive serological test for anti-AChR antibodies (lab test must be submitted) AND 2. The patient has a Myasthenia Gravis Foundation of America (MGFA) clinical classification class of II-IV AND 3. The patient has a MG-Activities of Daily Living total score of greater than or equal to 6 AND 4. ONE of the following: <ol style="list-style-type: none"> A. The prescriber has assessed the patient's current medications and discontinued any medications known to exacerbate myasthenia gravis (e.g., beta blockers, procainamide, quinidine, magnesium, anti-programmed death receptor-1 monoclonal antibodies, hydroxychloroquine, aminoglycosides) OR B. The prescriber has provided clinical rationale indicating that discontinuation of the offending agent is not clinically appropriate AND 5. ONE of the following: <ol style="list-style-type: none"> A. The patient has tried and had an inadequate response to at least 2 immunosuppressive therapies (e.g., azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate, cyclophosphamide) (either in combination or monotherapy) used for the treatment of myasthenia gravis OR B. The patient has an intolerance or hypersensitivity to at least 2 immunosuppressive therapies OR C. The patient has tried and had an inadequate response to treatment to at least 1 immunosuppressive therapy (e.g., azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate, cyclophosphamide) AND ONE of the following: <ol style="list-style-type: none"> 1. The patient required chronic intravenous immunoglobulin (IVIG) OR 2. The patient required chronic plasmapheresis/plasma exchange OR D. The patient has an intolerance or hypersensitivity to at least 1 immunosuppressant AND plasmapheresis/plasma exchange OR

Module	Clinical Criteria for Approval
	<p style="text-align: center;">E. The patient has an FDA labeled contraindication to ALL immunosuppressive therapies and plasmapheresis/plasma exchange OR</p> <p>D. The patient has another FDA approved indication for the requested agent AND</p> <p>2. ONE of the following:</p> <p style="padding-left: 20px;">A. The patient's age is within FDA labeling for the requested indication for the requested agent OR</p> <p style="padding-left: 20px;">B. The prescriber has provided information supporting the use of the requested agent for the patient's age for the requested indication AND</p> <p>3. The prescriber is a specialist in the area of the patient's diagnosis or the prescriber has consulted with a specialist in the area of the patient's diagnosis AND</p> <p>4. The patient will NOT be using the requested agent in combination with Soliris AND</p> <p>5. The patient does NOT have any FDA labeled contraindications to the requested agent AND</p> <p>6. The requested quantity (dose) is within FDA labeled dosing for the patient's weight</p> <p>Length of Approval: 6 months</p> <p>Ultomiris Renewal Evaluation:</p> <p>Ultomiris (ravulizumab-cwvz) will be approved when ALL of the following are met:</p> <p>1. The patient was previously approved for the requested agent through the plan's Medical Drug Review process AND</p> <p>2. ONE of the following:</p> <p style="padding-left: 20px;">A. The patient has a diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) AND BOTH of the following:</p> <p style="padding-left: 40px;">1. The prescriber has provided information that the patient has had clinical benefit with the requested agent (e.g., decreased requirement for RBC transfusions, stabilization/improvement of hemoglobin, reduction of lactate dehydrogenase (LDH), stabilization/improvement of symptoms (medical records required) AND</p> <p style="padding-left: 40px;">2. The patient will NOT be using the requested agent in combination with Empaveli (pegcetacoplan) for the requested indication OR</p> <p style="padding-left: 20px;">B. The patient has a diagnosis of Atypical Hemolytic Uremic Syndrome (aHUS) AND the prescriber has provided information that the patient has had clinical benefit with the requested agent (e.g., improved platelet count, reduction of lactate dehydrogenase (LDH), stabilization/improvement of renal function) (medical records required) OR</p> <p style="padding-left: 20px;">C. The patient has a diagnosis of generalized myasthenia gravis (gMG) AND the prescriber has provided information that the patient has had clinical benefit with the requested agent (e.g., improved MG-ADL total score, improved quantitative myasthenia gravis total score) (medical records required) AND</p> <p style="padding-left: 20px;">D. Another FDA approved indication for the requested agent AND the prescriber has provided information that the patient as had clinical benefit with the requested agent (e.g., improvement or stabilization of symptoms) (medical records required) AND</p> <p>3. The prescriber is a specialist in the area of the patient's diagnosis or the prescriber has consulted with a specialist in the area of the patient's diagnosis AND</p> <p>4. The patient will NOT be using the requested agent in combination with Soliris AND</p> <p>5. The patient does NOT have any FDA labeled contraindications to the requested agent AND</p> <p>6. The requested quantity (dose) is within FDA labeled dosing for the patient's weight</p> <p>Length of Approval: 12 months</p>